Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Switching treatments in COPD: implications for costs and treatment adherence

Authors Braido F, Lavorini F, Blasi F, Baiardini I, Canonica GW

Received 29 July 2015

Accepted for publication 3 October 2015

Published 3 December 2015 Volume 2015:10(1) Pages 2601—2608

DOI https://doi.org/10.2147/COPD.S79635

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Hsiao-Chi Chuang

Peer reviewer comments 5

Editor who approved publication: Dr Richard Russell

Fulvio Braido,1 Federico Lavorini,2 Francesco Blasi,3 Ilaria Baiardini,1,* Giorgio Walter Canonica1,*

1Respiratory and Allergy Diseases Clinic, Department of Internal Medicine, University of Genoa, IRCCS AOU San Martino-IST, Genoa, 2Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, 3Department of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

*These authors contributed equally to this work

Abstract: Inhaled therapy is key to the management of chronic obstructive pulmonary disease (COPD). New drugs and inhalers have recently been launched or will soon become available, and the expiry of patent protection covering several currently used inhaled bronchodilators and corticosteroids will be accompanied by the development of bioequivalent, generic inhaled drugs. Consequently, a broader availability of branded and generic compounds will increase prescription opportunities. Given the time course of COPD, patients are likely to switch drugs and inhalers in daily practice. Switching from one device to another, if not accompanied by appropriate training for the patient, can be associated with poor clinical outcomes and increased use of health care resources. In fact, while it seems reasonable to prescribe generic inhaled drugs to reduce costs, inadequate use of inhaler devices, which is often associated with a poor patient–physician or patient–pharmacist relationship, is one of the most common reasons for failure to achieve COPD treatment outcomes. Further research is needed to quantify, as in asthma, the impact of inappropriate switching of inhalers in patients with COPD and show the outcomes related to the effect of using the same device for delivering inhaled medications.

Keywords: inhaled therapy, long-acting antimuscarinic agents, long-acting β2 agonists, inhaled corticosteroids, metered-dose inhalers, dry powder inhaler

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine

Sun HW, Wei C, Liu BS, Jing HM, Feng Q, Tong YN, Yang Y, Yang LY, Zuo QF, Zhang Y, Zou QM, Zeng H

International Journal of Nanomedicine 2015, 10:7275-7290

Published Date: 3 December 2015

Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD

Boixeda R, Almagro P, DĂ­ez-Manglano J, Cabrera FJ, Recio J, Martin-Garrido I, Soriano JB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2581-2591

Published Date: 1 December 2015

Prevalence of chronic obstructive pulmonary disease in asymptomatic smokers

Sansores RH, Velázquez-Uncal M, Pérez-Bautista O, Villalba-Caloca J, Falfán-Valencia R, Ramírez-Venegas A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2357-2363

Published Date: 2 November 2015

The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients

Darbà J, Ramírez G, Sicras A, Francoli P, Torvinen S, Sánchez-de la Rosa R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2335-2345

Published Date: 29 October 2015

The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units

Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Sandström T, Janson C

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2327-2334

Published Date: 28 October 2015

The stats are in: an update on statin use in COPD

Carlson AA, Smith EA, Reid DJ

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2277-2284

Published Date: 22 October 2015

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1015-1026

Published Date: 5 June 2015